|
1
|
Meng X and Fu R: miR-206 regulates 5-FU
resistance by targeting Bcl-2 in colon cancer cells. Onco Targets
Ther. 11:1757–1765. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Evert J, Pathak S, Sun XF and Zhang H: A
study on effect of oxaliplatin in MicroRNA expression in human
colon cancer. J Cancer. 9:2046–2053. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Y, Gong P, Hou JX, Huang W, Ma XP, Wang
YL, Li J, Cui XB and Li N: miR-34a regulates multidrug resistance
via positively modulating OAZ2 signaling in colon cancer cells. J
Immunol Res. 2018:74985142018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dou H, Shen R, Tao J, Huang L, Shi H, Chen
H, Wang Y and Wang T: Curcumin Suppresses the Colon Cancer
Proliferation by Inhibiting Wnt/β-catenin pathways via miR-130a.
Front Pharmacol. 8:8772017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li L and Ma BB: Colorectal cancer in
Chinese patients: Current and emerging treatment options. Onco
Targets Ther. 7:1817–1828. 2014.PubMed/NCBI
|
|
6
|
Mishra J, Drummond J, Quazi SH, Karanki
SS, Shaw JJ, Chen B and Kumar N: Prospective of colon cancer
treatments and scope for combinatorial approach to enhanced cancer
cell apoptosis. Crit Rev Oncol Hematol. 86:232–250. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu YR, Liang L, Zhao JM, Zhang Y, Zhang
M, Zhong WL, Zhang Q, Wei JJ, Li M, Yuan J, et al: Twist1 confers
multidrug resistance in colon cancer through upregulation of
ATP-binding cassette transporters. Oncotarget. 8:52901–52912.
2017.PubMed/NCBI
|
|
8
|
He K, Chen D, Ruan H, Li X, Tong J, Xu X,
Zhang L and Yu J: BRAFV600E-dependent Mcl-1 stabilization leads to
everolimus resistance in colon cancer cells. Oncotarget.
7:47699–47710. 2016.PubMed/NCBI
|
|
9
|
Segditsas S and Tomlinson I: Colorectal
cancer and genetic alterations in the Wnt pathway. Oncogene.
25:7531–7537. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hollis M, Nair K, Vyas A, Chaturvedi LS,
Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer:
Early detection, prognosis, and chemosensitivity. World J
Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu YJ, Nangia-Makker P, Farhana L and
Majumdar APN: A novel mechanism of lncRNA and miRNA interaction:
CCAT2 regulates miR-145 expression by suppressing its maturation
process in colon cancer cells. Mol Cancer. 16:1552017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gong Z, Liu J, Xie X, Xu X, Wu P, Li H,
Wang Y, Li W and Xiong J: Identification of potential target genes
of USP22 via ChIP-seq and RNA-seq analysis in HeLa cells. Genet Mol
Biol. 41:488–495. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang A, Ning Z, Lu C, Gao W, Liang J, Yan
Q, Tan G and Liu J: USP22 induces cisplatin resistance in lung
adenocarcinoma by regulating γH2AX-Mediated DNA damage repair and
Ku70/Bax-mediated apoptosis. Front Pharmacol. 8:2742017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM
and Baek KH: The expression patterns of deubiquitinating enzymes,
USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Armour SM, Bennett EJ, Braun CR, Zhang XY,
McMahon SB, Gygi SP, Harper JW and Sinclair DA: A high-confidence
interaction map identifies SIRT1 as a mediator of acetylation of
USP22 and the SAGA coactivator complex. Mol Cell Biol.
33:1487–1502. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang XY, Varthi M, Sykes SM, Phillips C,
Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB: The
putative cancer stem cell marker USP22 is a subunit of the human
SAGA complex required for activated transcription and cell-cycle
progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang X, Zang H, Luo Y, Wu J, Fang Z, Zhu W
and Li Y: High expression of USP22 predicts poor prognosis and
advanced clinicopathological features in solid tumors: A
meta-analysis. Onco Targets Ther. 11:3035–3046. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hoeller D and Dikic I: Targeting the
ubiquitin system in cancer therapy. Nature. 458:438–444. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma Y, Fu HL, Wang Z, Huang H, Ni J, Song
J, Xia Y, Jin WL and Cui DX: USP22 maintains gastric cancer stem
cell stemness and promotes gastric cancer progression by
stabilizing BMI1 protein. Oncotarget. 8:33329–33342.
2017.PubMed/NCBI
|
|
20
|
Ling S, Li J, Shan Q, Dai H, Lu D, Wen X,
Song P, Xie H, Zhou L, Liu J, et al: USP22 mediates the multidrug
resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1
signaling pathway. Mol Oncol. 11:682–695. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu G, Cai J, Wang L, Jiang LY, Huang JB,
Hu R and Ding F: MicroRNA-30e-5p suppresses non-small cell lung
cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3
signaling. Exp Cell Res. 362:268–278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim D, Hong A, Park HI, Shin WH, Yoo L,
Jeon SJ and Chung KC: Deubiquitinating enzyme USP22 positively
regulates c-Myc stability and tumorigenic activity in mammalian and
breast cancer cells. J Cell Physiol. 232:3664–3676. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO classification of tumours of the digestive
system4th. 3. International Agency for Research on Cancer; Lyon:
2010
|
|
24
|
Wang B, Wu ZS and Wu Q: CMIP promotes
proliferation and metastasis in human glioma. Biomed Res Int.
2017:53401602017.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ,
Li SX, Wang XL and Peng ZH: Expression level of Bmi-1 oncoprotein
is associated with progression and prognosis in colon cancer. J
Cancer Res Clin Oncol. 136:997–1006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Z, Bu X, Chen H, Wang Q and Sha W:
Bmi-1 promotes the invasion and migration of colon cancer stem
cells through the downregulation of E-cadherin. Int J Mol Med.
38:1199–1207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schlormann W, Naumann S, Renner C and Glei
M: Influence of miRNA-106b and miRNA-135a on butyrate-regulated
expression of p21 and Cyclin D2 in human colon adenoma cells. Genes
Nutr. 10:502015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li ZH, Yu Y, Du C, Fu H, Wang J and Tian
Y: RNA interference-mediated USP22 gene silencing promotes human
brain glioma apoptosis and induces cell cycle arrest. Oncol Lett.
5:1290–1294. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Z, Zhu L, Guo T, Wang Y and Yang J:
Decreased H2B monoubiquitination and overexpression of
ubiquitin-specific protease enzyme 22 in malignant colon carcinoma.
Hum Pathol. 46:1006–1014. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ao N and Liu Y, Bian X, Feng H and Liu Y:
Ubiquitin-specific peptidase 22 inhibits colon cancer cell invasion
by suppressing the signal transducer and activator of transcription
3/matrix metalloproteinase 9 pathway. Mol Med Rep. 12:2107–2113.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang B, Tang F, Li B, Yuan SG, Xu Q,
Tomlinson S, Jin JF, Hu W and He SQ: High USP22 expression
indicates poor prognosis in hepatocellular carcinoma. Oncotarget.
6:12654–12667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao H, Tang H, Huang Q, Qiu B, Liu X, Fan
D, Gong L, Guo H, Chen C, Lei S, et al: MiR-101 targets USP22 to
inhibit the tumorigenesis of papillary thyroid carcinoma. Am J
Cancer Res. 6:2575–2586. 2016.PubMed/NCBI
|
|
34
|
Shao Y, Zhang D, Li X, Yang J, Chen L,
Ning Z, Xu Y, Deng G, Tao M, Zhu Y and Jiang J: MicroRNA-203
increases cell radiosensitivity via directly targeting Bmi-1 in
hepatocellular carcinoma. Mol Pharm. 15:3205–3215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim JS, Choi DW, Kim CS, Yu SK, Kim HJ, Go
DS, Lee SA, Moon SM, Kim SG, Chun HS, et al: MicroRNA-203 induces
apoptosis by targeting Bmi-1 in YD-38 oral cancer cells. Anticancer
Res. 38:3477–3485. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yan Y, Wang Y, Zhao P, Ma W, Hu Z and
Zhang K: BMI-1 promotes self-renewal of radio- and temozolomide
(TMZ)-resistant breast cancer cells. Reprod Sci. 24:1620–1629.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li N, Jiang K, Fang LP, Yao LL and Yu Z:
Knockdown of long noncoding RNA CCAT1 inhibits cell growth,
invasion and peritoneal metastasis via downregulation of Bmi-1 in
gastric cancer. Neoplasma. 65:736–744. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Koh H, Park H, Chandimali N, Huynh DL,
Zhang JJ, Ghosh M, Gera M, Kim N, Bak Y, Yoon DY, et al:
MicroRNA-128 suppresses paclitaxel-resistant lung cancer by
inhibiting MUC1-C and BMI-1 in cancer stem cells. Oncotarget.
8:110540–110551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Xue J, Kuang H, Zhou X, Liao L and
Yin F: microRNA-1297 inhibits the growth and metastasis of
colorectal cancer by suppressing Cyclin D2 expression. DNA Cell
Biol. 36:991–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhong H, Yang J, Zhang B, Wang X, Pei L,
Zhang L, Lin Z, Wang Y and Wang C: LncRNA GACAT3 predicts poor
prognosis and promotes cell proliferation in breast cancer through
regulation of miR-497/CCND2. Cancer Biomark. 22:787–797. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang F, Zhao H, Du Z and Jiang H: MiR-615
inhibits prostate cancer cell proliferation and invasion by
directly targeting Cyclin D2. Oncol Res. 27:293–299. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zeng Q, Tao X, Huang F, Wu T, Wang J,
Jiang X, Kuang Z and Cheng B: Overexpression of miR-155 promotes
the proliferation and invasion of oral squamous carcinoma cells by
regulating BCL6/Cyclin D2. Int J Mol Med. 37:1274–1280. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li YL, Wang J, Zhang CY, Shen YQ, Wang HM,
Ding L, Gu YC, Lou JT, Zhao XT, Ma ZL and Jin YX: MiR-146a-5p
inhibits cell proliferation and cell cycle progression in NSCLC
cell lines by targeting CCND1 and CCND2. Oncotarget. 7:59287–59298.
2016.PubMed/NCBI
|
